Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > History Repeats

<< Previous

Bullboard Posts

Next >>

Comment by venture009on Nov 09, 2023 10:03am

120 Views

Post# 35725881

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:History Repeats

Azzak, what type of announcement are you expecting? We are now trending toward the NASDQ $1 requirement and we all need to be concerned. There seems to be no support for the price. As pointed out here, there have been so many screw ups by this management that there is very little chance that investors want to take a risk with these guys anymore.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China